Lupin Launches Generic Zemuron Injection in the United States

09 Nov, 2023

Lupin Launches Generic Zemuron Injection in the United States

Global pharmaceutical company Lupin made a significant announcement on Wednesday with the launch of Rocuronium Bromide Injection, the generic counterpart of Zemuron Injection, in the United States. This development follows the approval of the abbreviated New Drug Application (ANDA) submitted by its alliance partner Caplin Steriles, sanctioned by the United States Food and Drug Administration (US FDA).

The recently presented Rocuronium Bromide Infusion is accessible in two details — 50 milligrams for every 5 milliliters (10 milligrams for each milliliter) and 100 milligrams for every 10 milliliters (10 milligrams for each milliliter) Different Portion Vials. Serving as a neuromuscular blocking agent, the drug aids in rapid sequence and routine tracheal intubation, offering skeletal muscle relaxation during surgical procedures or mechanical ventilation. According to IQVIA MAT data from August 2023, the drug's estimated annual sales in the US amount to $54 million.

In a strategic move in September, Lupin also disclosed its agreement with A. Menarini AsiaPacific Property, a completely claimed auxiliary of the Italian drug organization Menarini Gathering. The agreement involved the acquisition of five legacy brands, along with associated trademark rights, in crucial therapy areas such as Gastroenterology, Urology, and Anti-infectives. The monetary subtleties of this exchange stay undisclosed.

For the fiscal year 2023, Lupin demonstrated its commitment to innovation by investing 7.9% of its revenue in research and development. Operating across 15 manufacturing sites and seven research centers, the company focuses on the development and commercialization of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) across more than 100 markets globally.